Asciminib With or Without Sildenafil for Brain Tumors

NCT ID: NCT07039760

Last Updated: 2025-12-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2027-08-31

Brief Summary

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.

Conditions

Brain Tumor

Keywords

Asciminib; Sildenafil; ABL1; ABL2; Tyrosine kinase inhibitor; Pediatric brain tumor; Brain tumor; Pharmacokinetics; Pharmacodynamics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A: Asciminib

Patients will receive 1.3 mg/kg oral asciminib 12 +/- 1.5 hours prior to a second dose of 1.3 mg/kg oral asciminib. Surgery or biopsy will take place 3 +/- 1.5 hours after last dose.

Group Type: EXPERIMENTAL

Asciminib

Intervention Type: DRUG

Commercially available stock

Surgical resection or biopsy

Intervention Type: PROCEDURE

Standard of care

Group B: Asciminib + Sildenafil

Patients will receive 1.3 mg/kg oral asciminib plus 20 mg sildenafil (10 mg if \< 20 kg) 12 +/- 1.5 hours prior to a second dose of 1/3 mg/kg asciminib plus 20 mg (10 mg if \< 20 kg) sildenafil. Surgery or biopsy will take place 3 +/- 1.5 hours after last dose.

Group Type: EXPERIMENTAL

Asciminib

Intervention Type: DRUG

Commercially available stock

Sildenafil

Intervention Type: DRUG

Commercially available stock

Surgical resection or biopsy

Intervention Type: PROCEDURE

Standard of care

Interventions

Asciminib

Commercially available stock

Intervention Type: DRUG

Sildenafil

Commercially available stock

Intervention Type: DRUG

Surgical resection or biopsy

Standard of care

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Ages 6-25 years old, inclusive.
• Radiographic evidence of a recurrent/progressive brain tumor.
• Tumor must be predominantly in an intraparenchymal location.
• Deemed operable (able to be resected or have an open or stereotactic needle biopsy) by treating neurosurgeon.
• Karnofsky/Lansky Performance Status of ≥ 60. Patients who are unable to walk because of paralysis but who are up in a wheelchair will be considered ambulatory for the purposes of the performance score.
• Bone Marrow:

• ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported).
• Platelets ≥ 100,000/µl (may be supported by transfusion).
• Hemoglobin > 8 g/dL (may be supported by transfusion).
• Renal:

• Serum creatinine ≤ upper limit of institutional normal.
• Hepatic:

• Bilirubin ≤ 1.5 times upper limit of normal for age.
• ALT (SGPT) ≤ 3 times institutional upper limit of normal for age.
• AST (SGOT) ≤ 3 times institutional upper limit of normal for age.
• Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants. All patients and/or their parents or legal guardians must sign an IRB approved written informed consent document.

Exclusion Criteria

• Tumors suspected to be pituitary tumors or tumors of the meninges.
• Diagnosis of atypical teratoid rhabdoid tumor (ATRT) or diagnosis of pilocytic astrocytoma (PA).
• Unable to take tablets orally
• Pregnant and/or breastfeeding. Subjects of childbearing potential must have a negative serum or urine pregnancy test within 10 days prior to Day 1.
• Active infection requiring treatment or an unexplained febrile (> 101.5o F) illness.
• Known immunosuppressive disease or human immunodeficiency virus infection.
• Any active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease.
• Any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
• Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 25 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Thompson, M.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Washington University School of Medicine/St. Louis Children's Hospital

St Louis, Missouri, United States

Countries

United States

Central Contacts

Eric Thompson, M.D.

Role: CONTACT

Phone: 314-454-4707

Email: pedshemonctrialreferral@wustl.edu

Facility Contacts

Eric Thompson, M.D.

Role: primary

Related Links

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

202509139

Identifier Type: -

Identifier Source: org_study_id